---
title: "Seawolf Therapeutics signs $1.2bn deal with Sanofi"
publisher: "Stockmark.IT"
author: "Stockmark.IT Website"
published: "2026-11-18T06:53:21+00:00"
modified: "2026-11-18T06:53:21+00:00"
date: 2026-11-18
canonical: "https://stockmark.it/seawolf-therapeutics-and-sanofi-agree-1-2bn-drug-deal/"
category: "Trade Deal"
categories: ["Trade Deal"]
image: "https://i0.wp.com/stockmark.it/wp-content/uploads/2026/11/seawolf-therapeutics-signs-1-2bn-deal-with-sanofi.jpg?fit=1200%2C800&quality=89&ssl=1"
format: "news"
language: "en-GB"
---

# Seawolf Therapeutics signs $1.2bn deal with Sanofi

**Published:** November 18, 2026
**Author:** Stockmark.IT Website
**Categories:** Trade Deal
**Featured image:** ![Seawolf Therapeutics signs $1.2bn deal with Sanofi](https://i0.wp.com/stockmark.it/wp-content/uploads/2026/11/seawolf-therapeutics-signs-1-2bn-deal-with-sanofi.jpg?fit=1200%2C800&quality=89&ssl=1)

---

US gene therapy company Seawolf Therapeutics has entered into a multi-target research partnership and exclusive licensing agreement with Sanofi. The deal, valued at up to $1.2bn, focuses on developing treatments for bleeding disorders and other undisclosed indications. Under the terms, Seawolf is eligible for research, development, and commercial milestone payments, as well as tiered royalties on future sales of any resulting therapies.

The alliance coincides with Seawolf emerging from stealth mode with $100m in financing to advance its pipeline of DNA-based medicines. This funding includes seed financing led by founding investor Versant Ventures, followed by a Series A round supported by MPM BioImpact, Novartis Venture Fund, and Versant Ventures. Other participants in the financing included Alexandria Venture Investments, CRISPR Therapeutics, Eli Lilly and Company, Pathway to Cures, and Sixty Degree Capital.

Seawolf will use the capital to progress candidates built upon its Targeted RNA-Induced DNA Expression via Nuclear Translocation (TRIDENT) platform. The technology uses lipid nanoparticles to transport immune-quiet DNA encoding a therapeutic transgene directly into cell nuclei, aided by an auxiliary factor. This nuclear delivery aims to achieve stable, long-term therapeutic protein expression, overcoming the transient activity associated with standard RNA-based therapies. Unlike viral vectors, the nanoparticle delivery system allows repeated administration to adjust or supplement dosing over time. Seawolf has shown proof of concept for the approach in preclinical murine and non-human primate models of metabolic and rare diseases. In addition to collaborating with Sanofi, the company is advancing an internal lead programme targeting metabolic diseases.

---

**Original URL:** https://stockmark.it/seawolf-therapeutics-and-sanofi-agree-1-2bn-drug-deal/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*
